Page 59 - 2021_02-Haematologica-web

Risk stratification of CMV recurrence after HSCT
7. Ljungman P, Boeckh M, Hirsch HH, et al. Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. 2017;64(1):87- 91.
8.Lilleri D, Gerna G. Strategies to control human cytomegalovirus infection in adult hematopoietic stem cell transplant recipi- ents. Immunotherapy. 2016;8(9):1135-1149.
9. Ljungman P, de la Camara R, Robin C, et al. Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7). Lancet Infect Dis. 2019;19(8):e260- e272.
10. Krause H, Hebart H, Jahn G, Müller CA, Einsele H. Screening for CMV-specific T cell proliferation to identify patients at risk of developing late onset CMV disease. Bone Marrow Transplant. 1997;19(11):1111-1116.
11. Boeckh M, Leisenring W, Riddell SR, et al. Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2003;101(2):407-414.
12. Lamba R, Carrum G, Myers GD, et al. Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitu- tion following reduced intensity condition- ing allogeneic stem cell transplantation with alemtuzumab. Bone Marrow Transplant. 2005;36(9):797-802.
13. Ozdemir E, Saliba RM, Champlin RE, et al. Risk factors associated with late cytomegalovirus reactivation after allogene- ic stem cell transplantation for hematologi- cal malignancies. Bone Marrow Transplant. 2007;40(2):125-136.
14. Yong MK, Lewin SR, Manuel O. Immune monitoring for CMV in transplantation. Curr Infect Dis Rep. 2018;20(4):4.
15. Ciáurriz M, Zabalza A, Beloki L, et al. The immune response to cytomegalovirus in allogeneic hematopoietic stem cell trans- plant recipients. Cell Mol Life Sci. 2015;72(21):4049-4062.
16. Avetisyan G, Aschan J, Hägglund H, Ringdén O, Ljungman P. Evaluation of inter- vention strategy based on CMV-specific immune responses after allogeneic SCT. Bone Marrow Transplant. 2007;40(9):865- 869.
17. Moins-Teisserenc H, Busson M, Scieux C, et al. Patterns of cytomegalovirus reactivation are associated with distinct evolutive pro- files of immune reconstitution after allo- geneic hematopoietic stem cell transplanta- tion. J Infect Dis. 2008;198(6):818-826.
18. Gratama JW, Brooimans RA, van der Holt B, et al. Monitoring cytomegalovirus IE-1 and pp65-specific CD4+ and CD8+ T-cell responses after allogeneic stem cell trans- plantation may identify patients at risk for recurrent CMV reactivations. Cytometry B Clin Cytom. 2008;74(4):211-220.
19. Gratama JW, Boeckh M, Nakamura R, et al. Immune monitoring with iTAg MHC tetramers for prediction of recurrent or per- sistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell trans- plant recipients: a prospective multicenter study. Blood. 2010;116(10):1655-1662.
20. Fleming T, Dunne J, Crowley B. Ex vivo monitoring of human cytomegalovirus-spe- cific CD8(+) T-cell responses using the QuantiFERON-CMV assay in allogeneic hematopoietic stem cell transplant recipients attending an Irish hospital. J Med Virol. 2010;82(3):433-440.
21. Borchers S, Luther S, Lips U, et al. Tetramer monitoring to assess risk factors for recur- rent cytomegalovirus reactivation and reconstitution of antiviral immunity post allogeneic hematopoietic stem cell trans- plantation. Transpl Infect Dis. 2011;13(3): 222-236.
22. Borchers S, Bremm M, Lehrnbecher T, et al. Sequential anti-cytomegalovirus response monitoring may allow prediction of cytomegalovirus reactivation after allogene- ic stem cell transplantation. PloS One. 2012;7(12):e50248.
23. Tey S-K, Kennedy GA, Cromer D, et al. Clinical assessment of anti-viral CD8+ T cell immune monitoring using QuantiFERON- CMV® assay to identify high risk allogeneic hematopoietic stem cell transplant patients with CMV infection complications. PloS One. 2013;8(10):e74744.
24. Lee SM, Kim YJ, Yoo KH, et al. Clinical use- fulness of monitoring cytomegalovirus-spe- cific immunity by Quantiferon-CMV in pediatric allogeneic hematopoietic stem cell transplantation recipients. Ann Lab Med. 2017;37(3):277-281.
25.Yong MK, Cameron PU, Slavin M, et al. Identifying cytomegalovirus complications using the quantiferon-CMV assay after allo- geneic hematopoietic stem cell transplanta- tion. J Infect Dis. 2017;215(11): 1684-1694. Barabas S, Spindler T, Kiener R, et al. An optimized IFN-γ ELISpot assay for the sensi- tive and standardized monitoring of CMV protein-reactive effector cells of cell-mediat- ed immunity. BMC Immunol. 2017;18(1):14.
27.Banas B, Böger CA, Lückhoff G, et al. Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients. BMC Immunol. 2017;18(1):15.
28. Barabas S, Gary R, Bauer T, et al. Urea-medi- ated cross-presentation of soluble Epstein- Barr virus BZLF1 protein. PLoS Pathog. 2008;4(11):e1000198.
29. Nesher L, Shah DP, Ariza-Heredia EJ, et al. Utility of the enzyme-linked immunospot interferon-γ-release assay to predict the risk of cytomegalovirus infection in hematopoi- etic cell transplant recipients. J Infect Dis. 2016;213(11):1701-1707.
30. Banas B, Steubl D, Renders L, et al. Clinical validation of a novel ELISpot-based in vitro diagnostic assay to monitor CMV-specific cell-mediated immunity in kidney trans- plant recipients: a multicenter, longitudinal, prospective, observational study. Transpl Int. 2018;31(4):436-450.
31. Ljungman P, Perez-Bercoff L, Jonsson J, et al. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation. Haematologica. 2006;91(1):78-83.
32. Hakki M, Riddell SR, Storek J, et al. Immune reconstitution to cytomegalovirus after allo- geneic hematopoietic stem cell transplanta- tion: impact of host factors, drug therapy, and subclinical reactivation. Blood. 2003;102(8):3060-3067.
33. Bae S, Jung J, Kim S-M, et al. The detailed kinetics of cytomegalovirus-specific T cell responses after hematopoietic stem cell transplantation: 1 Year Follow-up Data. Immune Netw. 2018;18(2):e2.
34. Meesing A, Razonable RR. Absolute lym- phocyte count thresholds: a simple, readily available tool to predict the risk of cytomegalovirus infection after transplanta- tion. Open Forum Infect. Dis. 2018;5 (10):ofy230.
35. Watanabe M, Kanda J, Hishizawa M, et al. Lymphocyte area under the curve as a pre-
dictive factor for viral infection after allo- genic hematopoietic stem cell transplanta- tion. Biol Blood Marrow Transplant. 2019;25(3):587-593.
26.
36.Gutiérrez A, Muñoz I, Solano C, et al. Reconstitution of lymphocyte populations and cytomegalovirus viremia or disease after allogeneic peripheral blood stem cell trans- plantation. J Med Virol. 2003;70(3):399-403. Rénard C, Barlogis V, Mialou V, et al. Lymphocyte subset reconstitution after unrelated cord blood or bone marrow trans- plantation in children. Br J Haematol. 2011;152(3):322-330.
38. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infec- tion after nonmyeloablative stem cell trans- plantation: potential role of Campath-1H in delaying immune reconstitution. Blood. 2002;99(12):4357-4363.
39. Hiwarkar P, Gajdosova E, Qasim W, et al. Frequent occurrence of cytomegalovirus retinitis during immune reconstitution war- rants regular ophthalmic screening in high- risk pediatric allogeneic hematopoietic stem cell transplant recipients. Clin Infect Dis. 2014;58(12):1700-1706.
40.Ogonek J, Kralj Juric M, Ghimire S, et al. Immune reconstitution after allogeneic hematopoietic stem cell transplantation. Front Immunol. 2016;7:507.
41. Stemberger C, Graef P, Odendahl M, et al. Lowest numbers of primary CD8(+) T cells can reconstitute protective immunity upon adoptive immunotherapy. Blood. 2014;124 (4):628-637.
42.Gabanti E, Lilleri D, Ripamonti F, et al. Reconstitution of human cytomegalovirus- specific CD4+ T cells is critical for control of virus reactivation in hematopoietic stem cell transplant recipients but does not prevent organ infection. Biol Blood Marrow Transplant. 2015;21(12):2192-2202.
43. Shams El-Din AA, El-Desoukey NA, Amin Tawadrous DG, et al. The potential associa- tion of CMV-specific CD8+ T lymphocyte reconstitution with the risk of CMV reacti- vation and persistency in post allogeneic stem cell transplant patients. Hematol Amst Neth. 2018;23(8):463-469.
44.Barron MA, Gao D, Springer KL, et al. Relationship of reconstituted adaptive and innate cytomegalovirus (CMV)-specific immune responses with CMV viremia in hematopoietic stem cell transplant recipi- ents. Clin Infect Dis. 2009;49(12):1777-1783.
45. Drylewicz J, Schellens IMM, Gaiser R, et al. Rapid reconstitution of CD4 T cells and NK cells protects against CMV-reactivation after allogeneic stem cell transplantation. J Transl Med. 2016;14(1):230.
46. Foster AE, Gottlieb DJ, Sartor M, Hertzberg MS, Bradstock KF. Cytomegalovirus-specific CD4+ and CD8+ T-cells follow a similar reconstitution pattern after allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2002;8(9):501-511.
47. Pourgheysari B, Piper KP, McLarnon A, et al. Early reconstitution of effector memory CD4+ CMV-specific T cells protects against CMV reactivation following allogeneic SCT. Bone Marrow Transplant. 2009;43(11):853- 861.
48. Lilleri D, Gerna G, Fornara C, et al. Prospective simultaneous quantification of human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in young recipi- ents of allogeneic hematopoietic stem cell transplants. Blood. 2006;108(4):1406-1412.
49.Widmann T, Sester U, Schmidt T, et al. Rapid reconstitution of CMV-specific T-cells after stem-cell transplantation. Eur J
37.
haematologica | 2021; 106(2)
373